CD19 CAR-T therapy for young patients with high-risk B-cell leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 clinical trial focuses on pediatric and adolescent patients diagnosed with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) who are considered very high-risk. The study aims to evaluate the effectiveness of CD19 CAR-T therapy as an alternative treatment for patients eligible for hematopoietic stem cell transplantation. Participants must be 25 years old or younger and have achieved hematologic complete remission after initial chemotherapy. The trial will assess the safety and efficacy of the SNUH-CD19-CAR-T intervention in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject eligibility criteria include individuals who are under the age of 25 at the time of SNUH-CD19-CAR-T administration. Confirmation of B-cell acute lymphoblastic leukemia diagnosed at the initial assessment by a treating physician for the first diagnosis is required. Immunophenotypic analysis of CD19 expression on leukemia cells must be confirmed through immune profiling at the time of the initial diagnosis of B-cell acute lymphoblastic leukemia. In patients experiencing hematologic relapse of B-cell acute lymphoblastic leukemia, CD19 expression should also be confirmed at the time of relapse confirmation.

Patients must achieve hematologic complete remission defined as less than 5% blasts in the bone marrow after the first-line or second-line chemotherapy (first salvage therapy). Eligible patients for hematopoietic stem cell transplantation, defined by indications for transplantation, include those meeting at least one of the following criteria:

1. Philadelphia chromosome-positive due to t(9;22)(q34;q11) translocation.
2. Hypodiploidy defined by fewer than 44 chromosomes.
3. E2A-HLF gene fusion due to t(17;19) translocation.
4. Detection of minimal residual disease (MRD) positive at 0.01% or higher by next-generation sequencing confirmed after consolidation therapy and maintenance therapy.
5. Failure of the first-line therapy.
6. Cases not meeting any of the above criteria but deemed eligible for hematopoietic stem cell transplantation based on the investigator's judgment.

Exclusion Criteria:

* Patients who have undergone hematopoietic stem cell transplantation.
* Individuals for whom an adequate or sufficient leukapheresis product suitable for the production of SNUH-CD19-CAR-T cannot be obtained or is unavailable.
* Those known to be infected with the human immunodeficiency virus (HIV).
* Presence of uncontrolled active infections, determined by the investigator's assessment. If appropriate treatment has been administered for the infection, and there are no signs of progression at the time of enrollment, it is considered controlled. Persistent fever without other symptoms is not interpreted as progressive infection.
* Women who are pregnant or breastfeeding.
* Individuals deemed clinically inappropriate for participation in the clinical trial based on the investigator's clinical judgment.

Where it's running

• Seoul National University Children's Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Hyoung Jin Kang, Professor
• Email: kanghj@snu.ac.kr
• Phone: 02-2072-3452

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prebiotic and Probiotic Combo for Constipation Symptoms

  This study tests whether adding 1-kestose to a probiotic (BBH112) helps adults with constipation-related symptoms see more relief and better quality of life.

  Recruiting Seoul National University Hospital · Seongnam-si, Gyeonggi-do · NCT07923279

• Rehabilitation data registry for spinal cord injury in Korea

  This study tests whether long‑term disability and function after spinal cord injury can be predicted by combining medical and socioeconomic information gathered during and after inpatient rehabilitation.

  Recruiting Seoul National University Hospital · Yangpyeong, Gyeonggi-do · NCT07901985

• RSV vaccine safety and immune response in lung transplant patients vs. healthy adults

  This study tests how well the RSV vaccine works and how safe it is in people who have had a lung transplant compared with healthy adults.

  Recruiting Phase 4 Seoul National University Hospital · Seoul, Jongno-Gu · NCT07895394

• CD19 CAR-T Therapy for Kids with Refractory Childhood SLE

  This study tests whether a patient’s own CD19 CAR-T cells can help children and young adults with severe, hard-to-treat lupus.

  Recruiting Phase 1 Seoul National University Hospital · Seoul · NCT07855302

• Remimazolam vs propofol for stable blood pressure during thoracic/abdominal endovascular aortic repair

  This trial tests whether remimazolam keeps blood pressure steadier than propofol during TEVAR or EVAR in adults.

  Recruiting Phase 4 Seoul National University Hospital · Seoul · NCT07806006

• Transitioning to Adult Care for Kids with Rare Endocrine Disorders

  We’re testing a structured transition program to help young adults move from pediatric to adult endocrine care and see if it improves staying in care and quality of life.

  Recruiting Seoul National University Hospital · Daegu and 10 other locations · NCT07786142

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.